Describe differences in cost of care and quality of life in similar patients treated with CABG or PTCA?
Extensive comparisons of markers of self-rated health quality of life assessments, physical function scores, and the time of returning to work or other productive life activities differed little between the PTCA and CABG patients in the BARI trial. Both interventional therapies were effective in improving quality of life. Comparative cost of the two treatments showed angioplasty to be less expensive initially, but as recurrent procedures were required in t he PTCA group, the cost of PTCA approached the cost of CABG by the end of five years of follow-up. At this time, CABG remained $2,000 more expensive than PTCA. However, patients with diabetes, three-vessel disease, and advanced age (markers suggesting more favorable outcomes with coronary surgery), also had a lower cost for a CABG strategy than for PTCA. PTCA was less expensive than CABG in non-diabetic, two-vessel disease and in younger patients. These results suggest that the most efficacious treatment also tended to be the most co
Related Questions
- Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
- What is the difference in the five-year survival of patients in the BARI trial treated with CABG or PTCA?
- Is NCI exploring the role of physical activity in the quality of life and prognosis of cancer patients?
